Clinical Trial

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-15
notable Enrollment reduced: 84 -> 34 participants 2026-05-15
Trial Details
NCT Number NCT07220577
Lead Sponsor Novartis Pharmaceuticals
Conditions Atopic Dermatitis
Enrollment 34 participants
Start Date 2025-11-10
Primary Completion 2027-05-17 (estimated)
Study Completion 2027-09-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-14